Drug Patents owned by Chemocentryx
1. List of Tavneos drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8906938 | CHEMOCENTRYX | C5aR antagonists |
Dec, 2029
(6 years from now) | |
| US8445515 | CHEMOCENTRYX | C5aR antagonists |
Feb, 2031
(7 years from now) | |
| US11603356 | CHEMOCENTRYX | Amorphous form of a complement component C5a receptor |
May, 2041
(18 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Oct 7, 2028 |
| New Chemical Entity Exclusivity (NCE) | Oct 7, 2026 |
Drugs and Companies using AVACOPAN ingredient
NCE-1 date: 2025-10-07
Market Authorisation Date: 07 October, 2021
Treatment: An adjunctive treatment of adult patients with tavneos (avacopan) with severe active anca-associated vasculitis (gpa and mpa) in combination with standard therapy including glucocorticoids
Dosage: CAPSULE;ORAL
TAVNEOS family patents
17
United States
5
European Union
4
Japan
3
Spain
3
Denmark
3
Portugal
3
Hungary
2
RS
2
Poland
2
China
2
Brazil
2
Canada
2
Croatia
2
Lithuania
2
Slovenia
1
Hong Kong
1
Ukraine
1
Singapore
1
Morocco
1
Argentina
1
EA
1
Norway
1
New Zealand
1
Korea, Republic of
1
Israel
1
Taiwan
1
Jordan
1
Mexico
1
Australia
1
Netherlands
1
South Africa
1
Colombia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic